Invictus announces Annual General Meeting Results
July 25 2019 - 3:03PM
Vancouver, BC, July 25, 2019 – INVICTUS MD STRATEGIES CORP.
(“Invictus” or the “Company”) (TSXV: GENE; OTCQX: IVITF; FRA:
8IS2) is pleased to report that at the Company’s Annual General
Meeting (the “Meeting”) held today in Vancouver, shareholders
received the consolidated audited financial statements of the
Company for the year ended January 31, 2019 and approved all of the
resolutions put forward at the Meeting, namely:
- Appointed Manning, Elliott, LLP, as auditor of the Company for
the ensuing year and authorized the directors to fix their
remuneration;
- Fixed the number of directors at five (5);
- Elected Trevor Dixon, Paul Sparkes, Keith Stein, Richard Lee
and Colin Kinsley as directors for the ensuing year; and
- Approved the Company’s incentive stock option plan.
Following the Meeting the Board of Directors appointed the
following officers:
Trevor Dixon – President and Chief Executive Officer
Harbir Toor – Chief Financial Officer
Marc Ripa - Chief Operating Officer
Kathy Love – Corporate Secretary
On Behalf of the Board
Trevor Dixon
Chief Executive Officer
Investor Relations 1-844-800-6086
E-Mail: connect@invictus-md.com
About Invictus
Invictus is a global cannabis company with a focus on the
Canadian cannabis space, offering a selection of products under a
wide range of cannabinoid profiles that fit the demand of the
Company’s medical clients and retail customers. The Company’s
integrated sales approach is defined by five pillars of
distribution including medical, adult-use, international, Licensed
Producer to Licensed Producer and sales to provinces.
To meet growing demand, Invictus is expanding its cultivation
footprint with three cannabis production facilities licensed under
the Cannabis Act, which replaced the Access to Cannabis for Medical
Purposes Regulations in Canada. Invictus’ wholly-owned subsidiary,
Acreage Pharms Ltd.’s (“Acreage”) Phase I and Phase II
facilities are in full production and Acreage is completing its
Phase III cultivation facility. AB Laboratories Inc., a company
which is a 50% owned subsidiary of Invictus continues its
cultivation facility expansion. Invictus’ wholly owned subsidiary
0989561 B.C. Ltd. (dba Canandia Bioceuticals) Delta facility is a
licensed producer and has received its sales license issued by
Health Canada under the Cannabis Act. Another of Invictus’
wholly owned subsidiaries, 2015059 Alberta Ltd. (dba Leaf Wise),
continues to connect medical clients to physicians for medical
cannabis and to Invictus’ fully licensed cannabis producers under
the Cannabis Act. Future Harvest Development Ltd., a company
which is a 82.5% owned subsidiary of Invictus continues to produce
high-quality fertilizer and nutrients which are supplied to
licensed cannabis producers. Invictus is targeting up to 50 percent
of production to medical cannabis. Invictus drives sustainable
long-term shareholder value by continuing to develop Invictus’
Canadian production of medical and recreational cannabis products.
For more information visit www.invictus-md.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
Kathy Love
Invictus
kathy@invictus-md.com
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024